Application of Shinorine production engineering strain in skin repair
By constructing Shinorine production engineering strains, using them to induce fermentation in E. coli to obtain crude extracts, the problems of single and high cost of existing sunscreen products are solved, and efficient skin repair and anti-aging effects are achieved.
Patent Information
- Application Number
- CN202411229064.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-03
- Publication Date
- 2024-11-19
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The existing sunscreen products have single effect, the amount of chemical protective agent added exceeds the standard, and the natural production of Shinorine is low efficiency and high cost, and the artificial synthesis cycle is long and expensive, making it difficult to meet the skin's needs for ultraviolet protection and repair.
Shinorine production engineering strain was constructed, and the engineering strains were constructed in E. coli using four key enzyme genes mysA3, mysB3, mysC3 and mysD3 from the Shinorine synthetic gene cluster from the algae strain Nostoc linkia NIES-25. The crude Shinorine containing crude was obtained by inducing fermentation. Extract for skin repair and anti-aging.
The crude extract without Shinorine purification can promote skin cell repair and anti-aging, improve the skin's effectiveness against UV protection, reduce production costs, and improve yield stability.
Smart Images

Figure CN118975970A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the field of biotechnology, in particular to application of a Shinorine production engineering strain in skin repair. Background Art
[0002] In recent years, due to the serious depletion of the ozone layer, the ultraviolet rays reaching the earth's surface have increased day by day. Excessive ultraviolet radiation will accelerate the photoaging of the skin, posing a serious threat to human skin health. Skin photoaging will break the dynamic balance of oxidative stress response in the body. Excessive reactive oxygen free radicals will induce the increase of matrix metalloproteinase expression related to photoaging in skin tissue through the NF-kB signaling pathway, destroy the cross-linking of collagen in the tissue, and make the skin loose. After long-term accumulation, it will lead to skin damage and irreversible aging.
[0003] At present, most of the sunscreen cosmetics developed and produced on the market have shortcomings such as single effect and excessive amount of chemical protective agents added. Therefore, extracting UV protective agents from natural plants has become the focus of current research.
[0004] Mycosporine-like amino acids (MAAs) are a class of water-soluble active substances that use cyclohexenone as the basic skeleton and are formed by condensation with various types of amino acids. They are widely found in large red algae and are a class of active substances with good application prospects. Shinorine is a type of MAAs that not only has the ability to absorb ultraviolet rays, but is also biodegradable. However, the natural production of Shinorine is inefficient and costly, and the output may also vary with the seasons and geographical locations, limiting supply. In addition to natural production, Shinorine can also be artificially synthesized by chemical methods, but the chemical method has a long production cycle and is extremely expensive.
[0005] In order to further develop the application of Shinorine in skin repair, the present invention constructs a Shinorine production engineering strain and explores the potential benefits of the engineering strain in promoting cell repair and anti-aging. Summary of the invention
[0006] The invention provides an application of a Shinorine production engineering strain in skin repair. Firstly, four key enzyme genes mysA3, mysB3, mysC3 and mysD3 in a Shinorine synthesis gene cluster from an algae strain Nostoc linkia NIES-25 are used to construct an Escherichia coli engineering strain, and then the engineering strain is induced to ferment to obtain a crude extract containing Shinorine. Experimental verification shows that the crude extract has the effects of promoting skin cell repair and anti-aging without the need for Shinorine purification.
[0007] The technical solution of the present invention is as follows:
[0008] Application of a Shinorine production engineered strain in skin repair;
[0009] The Shinorine production engineering strain is obtained by introducing AB gene fragments and CD gene fragments into Escherichia coli via a vector, the nucleotide sequence of the AB gene fragment is shown in SEQ ID NO.4, and the nucleotide sequence of the CD gene fragment is shown in SEQ ID NO.5.
[0010] Preferably, the vector is a pETDuet1 plasmid vector.
[0011] Further preferably, the introduction positions of the AB gene fragment and the CD gene fragment in the pETDuet1 plasmid vector are: the AB gene fragment is seamlessly cloned into the PstI restriction site of the pETDuet1 plasmid vector, and the CD gene fragment is introduced between the NdeI-XhoI restriction sites of the pETDuet1 plasmid vector.
[0012] Preferably, the skin repair is cell repair and / or anti-aging.
[0013] Preferably, the cell repair is skin keratinocyte (HaCaT) repair and / or human skin fibroblast (HSF) repair.
[0014] Preferably, the Shinorine production engineering strain further contains a T7 promoter, and the nucleotide sequence of the T7 promoter is shown in SEQ ID NO.28.
[0015] Further preferably, the method for constructing the Shinorine production engineering strain containing the T7 promoter comprises the following steps:
[0016] (1) Using the AB gene fragment as a template, PCR amplification was performed using primers mysA3-F and mysA3-R to obtain the gene fragment mysA3, wherein the primer sequences of mysA3-F and mysA3-R are shown in SEQ ID NOs. 18 to 19;
[0017] Using the AB gene fragment as a template, primers mysB3-F and mysB3-R were used to perform PCR amplification to obtain the gene fragment mysB3, wherein the primer sequences of mysB3-F and mysB3-R are shown in SEQ ID NOs. 20-21;
[0018] The plasmid pRSFDuet1 was double-digested with NcoI and NotI and purified and recovered to obtain the pRSFDuet1 vector fragment;
[0019] The gene fragment mysA3, the gene fragment mysB3 and the pRSFDuet1 vector fragment were connected, and the connection product was transformed into E. coli XL1-Blue to obtain the recombinant plasmid pRSFDuet1-mysA3B3;
[0020] (2) Using pRSFDuet1 as a template, PCR amplification was performed using primers pRSF-T7-Not-F and pRSF-T7-Nde-R to obtain the T7 promoter, wherein the primer sequences of pRSF-T7-Not-F and pRSF-T7-Nde-R are shown in SEQ ID NOs. 22 to 23;
[0021] Using the CD gene fragment as a template, primers mysC3-F and mysC3-R were used to perform PCR amplification to obtain the gene fragment mysC3, wherein the primer sequences of the mysC3-F and mysC3-R are shown in SEQ ID NOs. 24-25;
[0022] Using the CD gene fragment as a template, primers mysD3-F and mysD3-R were used to perform PCR amplification to obtain the gene fragment mysD3, wherein the primer sequences of the mysD3-F and mysD3-R are shown in SEQ ID NOs. 26-27;
[0023] (3) The recombinant plasmid pRSFDuet1-mysA3B3 of step (1) is double-digested with enzymes NdeI and XhoI and purified and recovered to obtain a pRSFDuet1-mysA3B3 vector fragment;
[0024] (4) Connect the T7 promoter, gene fragment mysC3, gene fragment mysD3, and pRSFDuet1-mysA3B3 vector fragment, and transform the connection product into E. coli XL1-Blue to obtain the recombinant plasmid pRSFDuet1-T7×4-mysA3B3C3D3;
[0025] (5) The recombinant plasmid pRSFDuet1-T7×4-mysA3B3C3D3 was transformed into E. coli BL21 to obtain a Shinorine production engineering strain containing the T7 promoter.
[0026] Preferably, the application of the Shinorine production engineering strain in skin repair is as follows: inoculating the bacterial liquid of the Shinorine production engineering strain into LB liquid culture medium for cultivation, and culturing to an OD value of 0. 600 When the pH value is 0.5 to 0.7, IPTG is added at a final concentration of 0.1 to 0.5 mM, and the culture is induced at a culture temperature of 25 to 30°C for 20 to 36 hours to obtain a fermentation liquid containing Shinorine.
[0027] Further preferably, the bacteria in the fermentation broth are collected, washed with PBS buffer and resuspended, the resuspended liquid is subjected to a first sonication and centrifugation, the supernatant is collected, methanol is added to the supernatant for extraction, and then sonication and centrifugation are performed for a second time, the supernatant is collected, and the supernatant is subjected to rotary evaporation at 30-35°C and freeze-drying at -70°C to obtain a lyophilized crude extract containing Shinorine.
[0028] Further preferably, the conditions for the first ultrasonic centrifugation are: power 400w, ultrasonic time 20min; the conditions for the second ultrasonic centrifugation are: power 100w, ultrasonic time 1h.
[0029] Further preferably, the final concentration of IPTG is 0.2 mM.
[0030] Beneficial effects:
[0031] The present invention provides a Shinorine production engineering strain and explores its application in skin repair. Firstly, four key enzyme genes mysA3, mysB3, mysC3 and mysD3 in the Shinorine synthesis gene cluster from the algae strain Nostoc linkia NIES-25 are used to construct an Escherichia coli engineering strain, and then the engineering strain is induced to ferment to obtain an intracellular crude extract containing Shinorine. Experimental verification shows that the crude extract has the effects of promoting skin cell repair and anti-aging without the need for Shinorine purification. BRIEF DESCRIPTION OF THE DRAWINGS
[0032] Figure 1 This is a graph showing the protein expression of E.coli BL21-Ⅰ, E.coli BL21-Ⅱ, and E.coli BL21-Ⅲ.
[0033] Figure 2 This is a graph showing the protein expression of E.coli BL21-Ⅲ and E.coli BL21 / pRSFDuet1-T7×4-mysA3B3C3D3.
[0034] Figure 3 This is the HPLC detection spectrum of E.coli BL21 blank control.
[0035] Figure 4 This is the HPLC detection spectrum of E.coli BL21-Ⅲ.
[0036] Figure 5 This is the HPLC detection spectrum of E.coli BL21 / pRSFDuet1-T7×4-mysA3B3C3D3.
[0037] Figure 6 Comparison of Shinorine and Mycosporine-glycine production of E. coli BL21-Ⅲ and E. coli BL21 / pRSFDuet1-T7×4-mysA3B3C3D3.
[0038] Figure 7 The toxicity test results of Shinorine on HaCaT.
[0039] Figure 8 The toxicity test results of Shinorine on HSF.
[0040] Fig. 9 The results of Shinorine's scratch repair test on HaCaT cells.
[0041] Fig.10 The results of the cell scratch repair test of Shinorine on HSF.
[0042] Fig.11 This is the detection result of MMP-1 expression.
[0043] Fig.12 The expression level of COL-1 was detected. DETAILED DESCRIPTION
[0044] The following is explained in conjunction with specific embodiments:
[0045] (1) Source of experimental materials:
[0046] pRSFDuet1 plasmid: purchased from Paisono Biotech Co., Ltd.;
[0047] pET22b, pETDuet1, E. coli XL1-Blue, E. coli BL21: from the Biological Laboratory of Qilu University of Technology, all are conventional commercial products.
[0048] Human skin keratinocytes (HaCaT) were purchased from Hunan Fenghui Biotechnology Co., Ltd.
[0049] Human skin fibroblasts (HSF): purchased from Shaanxi Boxi General Detection Technology Co., Ltd.
[0050] MMP-1 activity detection kit: purchased from Wuhan Boster Bioengineering Co., Ltd.
[0051] COL-1 activity detection kit: purchased from Wuhan Huamei Bioengineering Co., Ltd.
[0052] (2) Preparation of culture medium and main reagents used in the following examples:
[0053] PBS buffer: 8.0 g NaCl, 0.2 g KCl, 1.44 g Na2HPO4, 0.24 g KH2PO4, 1000 mL distilled water, HCl to adjust pH to 7.4.
[0054] SDS PAGE loading buffer: Take 1.25 mL of 1 M Tris-HCl buffer, 0.5 g of sodium dodecyl sulfate, 0.025 g of bromophenol blue, 2.5 mL of glycerol, and 0.25 mL of β-mercaptoethanol, and add ddH2O to 25 mL.
[0055] High glucose DMEM medium: purchased from Biological Industries (BI);
[0056] High-glucose DMEM complete medium: high-glucose DMEM medium was supplemented with 10% (v / v) FBS, 1% (100 μg / mL) penicillin, and 1% (100 μg / mL) streptomycin.
[0057] Low-glucose DMEM medium: purchased from Biological Industries (BI);
[0058] Low-glucose DMEM complete medium: Add 10% (v / v) FBS, 1% (100 μg / mL) penicillin, and 1% (100 μg / mL) streptomycin to the low-glucose DMEM medium.
[0059] Example 1: Construction of recombinant E. coli BL21-I, E. coli BL21-II, and E. coli BL21-III
[0060] 1. Mining, optimization and synthesis of shinorine synthetic genes
[0061] The inventors selected three Shinorine synthetic gene clusters, which were from Nostoc punctiforme ATCC29133, Anabaena variabilis ATCC 29413, and Nostoc linkia NIES-25, and sent the four key enzyme genes mysA, mysB, mysC and mysD in the Shinorine synthetic gene cluster to Paisonno Biotechnology for codon optimization and gene synthesis.
[0062] in:
[0063] The shinorine synthesis gene cluster from Nostoc punctiforme ATCC 29133 is gene cluster 1, which includes "ABC gene fragment" and "D gene fragment", the nucleotide sequence of the ABC gene fragment is shown in SEQ ID NO.1, and the nucleotide sequence of the D gene fragment is shown in SEQ ID NO.2; the four key enzyme genes in gene cluster 1 are respectively called "mysA1, mysB1, mysC1 and mysD1";
[0064] The shinorine synthesis gene cluster from Anabaena variabilis ATCC 29413 is gene cluster 2, and its nucleotide sequence is shown in SEQ ID NO.3, wherein the four key enzyme genes are respectively called "mysA2, mysB2, mysC2 and mysD2";
[0065] The shinorine synthesis gene cluster from Nostoc linkia NIES-25 is gene cluster 3, which includes "AB gene fragment" and "CD gene fragment", the nucleotide sequence of the AB gene fragment is shown in SEQ ID NO.4, and the nucleotide sequence of the CD gene fragment is shown in SEQ ID NO.5; the four key enzyme genes in gene cluster 3 are respectively called "mysA3, mysB3, mysC3 and mysD3".
[0066] 2. Construction of each recombinant plasmid
[0067] (1) Construction of recombinant plasmid pETDuet1-mysA1B1
[0068] ① Using the ABC gene fragment in gene cluster 1 as a template, PCR amplification was performed using primers mysA1-F (SEQ ID NO.6) and mysA1-R (SEQ ID NO.7) to obtain the gene fragment mysA1.
[0069] ② The pETDuet1 plasmid was double-digested with NcoI and NotI. The double-digestion system is shown in Table 1 below:
[0070] Table 1. Double enzyme digestion system
[0071] Overall system 10μL NcoI 1μL NotI 1μL 10×Buffer 1μL pETDuet1 Plasmid 7μL
[0072] ③ Use a DNA purification and recovery kit to purify and recover the enzyme-digested product (about 5400 bp) to obtain the vector fragment.
[0073] ④Use ClonExpressⅡ one-step cloning kit to connect the gene fragment mysA1 and the vector fragment to obtain the recombinant plasmid pETDuet1-mysA1.
[0074] ⑤ The recombinant plasmid pETDuet1-mysA1 was double-digested with NdeI and XhoI, and the digestion product (about 6600bp) was recovered; the ABC gene fragment in gene cluster 1 was used as a template, and primers mysB1-F (SEQ ID NO.8) and mysB1-R (SEQ ID NO.9) were used for PCR amplification to obtain the gene fragment mysB1.
[0075] ⑥Use ClonExpressⅡ one-step cloning kit to connect the gene fragment mysB1 in step ⑤ with the enzyme digestion product to obtain the recombinant plasmid pETDuet1-mysA1B1.
[0076] (2) Construction of recombinant plasmid pRSFDuet1-mysC1D1
[0077] ① Using the ABC gene fragment in gene cluster 1 as a template, PCR amplification was performed using primers mysC1-F (SEQ ID NO.10) and mysC1-R (SEQ ID NO.11) to obtain the gene fragment mysC1.
[0078] ② The pRSFDuet1 plasmid was double-digested with NcoI and NotI, and the double-digestion system was the same as above.
[0079] ③ Use a DNA purification and recovery kit to purify and recover the enzyme-digested product (about 3800 bp) to obtain the vector fragment.
[0080] ④Use ClonExpressⅡone-step cloning kit to connect the gene fragment mysC1 and the vector fragment to obtain the recombinant plasmid pRSFDuet1-mysC1.
[0081] ⑤ The recombinant plasmid pRSFDuet1-mysC1 was double-digested with NdeI and XhoI, and the digestion product (about 5200bp) was recovered; the D gene fragment in gene cluster 1 was used as a template, and primers mysD1-F (SEQ ID NO.12) and mysD1-R (SEQ ID NO.13) were used for PCR amplification to obtain the gene fragment mysD1.
[0082] ⑥Use ClonExpressⅡ one-step cloning kit to connect the gene fragment mysD1 in step ⑤ with the enzyme digestion product to obtain the recombinant plasmid pRSFDuet1-mysC1D1.
[0083] (3) Construction of recombinant plasmid pET22b-mysA2B2C2
[0084] ① Using gene cluster 2 as a template, PCR amplification was performed using primers mysA2B2C2-F (SEQ ID NO.14) and mysA2B2C2-R (SEQ ID NO.15) to obtain the gene fragment mysA2B2C2.
[0085] ② The pET22b plasmid was double-digested with NdeI and XhoI, and the double-digestion system was the same as above.
[0086] ③ Use a DNA purification and recovery kit to purify and recover the enzyme-digested product (about 5500 bp) to obtain the vector fragment.
[0087] ④Use ClonExpressⅡ one-step cloning kit to connect the gene fragment mysA2B2C2 and the vector fragment to obtain the recombinant plasmid pET22b-mysA2B2C2.
[0088] (4) Construction of recombinant plasmid pRSFDuet1-mysD2
[0089] ① Using gene cluster 2 as a template, PCR amplification was performed using primers mysD2-F (SEQ ID NO.16) and mysD2-R (SEQ ID NO.17) to obtain the gene fragment mysD2.
[0090] ② The pRSFDuet1 plasmid was double-digested with NdeI and XhoI, and the double-digestion system was the same as above.
[0091] ③ Use a DNA purification and recovery kit to purify and recover the enzyme-digested product (about 3800 bp) to obtain the vector fragment.
[0092] ④Use ClonExpressⅡone-step cloning kit to connect the gene fragment mysD2 and the vector fragment to obtain the recombinant plasmid pRSFDuet1-mysD2.
[0093] (5) Construction of recombinant plasmid pETDuet1-mysA3B3C3D3
[0094] The construction process of the recombinant plasmid pETDuet1-mysA3B3C3D3 was directly completed by Nanjing Novozymes Co., Ltd. The specific construction method is: the AB gene fragment shown in SEQ ID NO.4 is seamlessly cloned into the PstI restriction site of the pETDuet1 plasmid vector, and the CD gene fragment shown in SEQ ID NO.5 is introduced between the NdeI-XhoI restriction sites of the pETDuet1 plasmid vector to obtain the recombinant plasmid pETDuet1-mysA3B3C3D3.
[0095] The PCR amplification system and PCR amplification program in the above steps (1) to (3) are shown in Table 2 and Table 3 respectively:
[0096] Table 2. PCR amplification system
[0097] Overall system 50μL <![CDATA[ddH2O]]> 20μL 2×Phanta Master Mix 25μL Upstream primer F 2μL Downstream primer R 2μL Target gene 1μL
[0098] Table 3. PCR amplification program
[0099] PCR procedure temperature time cycle Pre-denaturation 98℃ 30s 1 transsexual 98℃ 10s 30 annealing 50℃ 5s 30 extend 72℃ 10s 30 Final extension 72℃ 1min 1
[0100] 3. Construction of recombinant E. coli BL21-Ⅰ, E. coli BL21-Ⅱ, and E. coli BL21-Ⅲ
[0101] Take out the competent cell E.coli XL1-Blue from the ultra-low temperature refrigerator and place it on ice for later use; pipette 10 μL of each recombinant plasmid in step (ii) and add it to the competent cells, blow gently to mix, then place it on ice for 30 minutes, then heat shock it in a 42°C water bath for 90 seconds, and immediately place it on ice for 2 minutes to obtain the transformation solution. Add 900 μL of LB liquid culture medium to the transformation solution, shake it at 37°C for 1 hour, centrifuge it at 6000rpm for 3 minutes, pipette off 500 μL of supernatant, gently mix the remaining supernatant and the bacteria to obtain a bacterial suspension, pipette 100 μL of the bacterial suspension onto LB solid culture medium containing 50 μg / mL Kan and 50 μg / mL Amp, and culture it at 37°C for 12 hours until a single colony grows;
[0102] Single colonies were picked for preliminary verification by colony PCR. Single colonies that were successfully verified by PCR were picked for bacterial culture, plasmid extraction and sequencing. The plasmids with correct sequencing results were transformed into E. coli BL21 to construct recombinant E. coli. The specific transformation process is as follows (the transformation method is the same as above):
[0103] pETDuet1-mysA1B1 and pRSFDuet1-mysC1D1 were co-transformed into E. coli BL21 to obtain recombinant E. coli BL21-Ⅰ;
[0104] pET22b-mysA2B2C2 and pRSFDuet1-mysD2 were co-transformed into E. coli BL21 to obtain recombinant E. coli BL21-Ⅱ;
[0105] pETDuet1-mysA3B3C3D3 was transformed into E. coli BL21 to obtain recombinant E. coli BL21-Ⅲ.
[0106] The bacterial liquid of recombinant E. coli BL21-Ⅰ and E. coli BL21-Ⅱ were respectively spread on LB solid culture medium containing 50 μg / mL Kan and 50 μg / mL Amp, and the bacterial liquid of recombinant E. coli BL21-Ⅲ was spread on LB solid culture medium containing 50 μg / mL Amp; the above culture medium was cultured at 37°C for 12 hours until a single colony grew.
[0107] Single colonies were picked for colony PCR verification and sequencing. The bacterial suspensions of the recombinant strains E. coli BL21-Ⅰ and E. coli BL21-Ⅱ with correct sequencing results were inoculated at a ratio of 1% (v / v) into LB liquid culture medium containing 50 μg / mL Kan and 50 μg / mL Amp; the bacterial suspension of the recombinant strain E. coli BL21-Ⅲ with correct sequencing results was inoculated at a ratio of 1% (v / v) into LB liquid culture medium containing 50 μg / mL Amp; the cultures were shaken at 37°C for 1.5 h until OD 600 is about 0.6; add IPTG with a final concentration of 0.2mM and induce culture at 25℃ for 20h.
[0108] After the induction culture was completed, the culture solution was centrifuged at 10000 rpm for 5 min, the bacterial precipitate was collected, washed twice with PBS buffer and resuspended, and the resuspended solution was broken using an ultrasonic crusher (ultrasonication for 4 s and pause for 4 s), power 400 w, and ultrasonication for 20 min.
[0109] After the ultrasound is finished, the liquid after ultrasound is aspirated and added into SDS PAGE Loading buffer to prepare a whole-cell sample; the liquid after ultrasound is centrifuged at 10000 rpm for 10 min, and SDS PAGE Loading buffer is added into the supernatant to prepare a whole-cell sample.
[0110] The protein expression in whole cell samples and whole intracellular samples was analyzed by 12% SDS-PAGE. Figure 1 As shown, Figure A is a schematic diagram of the construction and gene cluster of E.coli BL21-Ⅰ, E.coli BL21-Ⅱ, and E.coli BL21-Ⅲ; Figure B is the SDS-PAGE analysis results of E.coli BL21-Ⅰ, E.coli BL21-Ⅱ, and E.coli BL21-Ⅲ, M: 180kDa Prestained Protein Marker, lanes 1-2: schematic diagram of whole cell and intracellular protein expression of E.coli BL21 blank control, lanes 3-4: schematic diagram of whole cell and intracellular protein expression of BL21-Ⅱ, lanes 5-6: schematic diagram of whole cell and intracellular protein expression of BL21-Ⅰ, lanes 7-8: schematic diagram of whole cell and intracellular protein expression of BL21-Ⅲ.
[0111] Depend on Figure 1 Available, E. coli BL21-Ⅰ, E. coli BL21-Ⅱ, E. coli The protein expression of BL21-Ⅲ is as follows: the protein band size of MysA (MysA1, MysA2, MysA3) is about 45kD; the protein band size of MysB (MysB1, MysB2, MysB3) is about 31kD; the protein band size of MysC (MysC1, MysC2, MysC3) is about 51kD; the sizes of MysD1 and MysD3 are 38kD, and MysD2 is about 97kD; all proteins are soluble proteins, and no inclusion bodies are produced, which indicates that the selected induction conditions are appropriate; in terms of protein expression level, the protein expression level of MysA is the highest among all enzymes, and the protein expression level of MysC is much lower than that of other proteins, so the synthesis of Shinorine will be limited by the expression of MysC; the protein expression level of MysB is slightly higher than that of MysD2, and the expression level of MysD2 is slightly higher than that of MysC; in addition, compared with E.coli The expression levels of E. coli BL21-Ⅰ, E. coli BL21-Ⅱ and E. coli BL21-Ⅲ gene clusters were the highest.
[0112] Example 2: Construction of the recombinant strain E. coli BL21 / pRSFDuet1-T7×4-mysA3B3C3D3 containing the cascade T7 promoter
[0113] Based on recombinant E. coli BL21-Ⅲ, a cascade T7 promoter strategy was adopted to promote the increase of shinorine synthesis by enhancing the protein expression level, wherein the nucleotide sequence of the T7 promoter is shown in SEQ ID NO. 28. The specific operation steps are as follows:
[0114] ① Using the AB gene fragment as a template, PCR amplification was performed using primers mysA3-F (SEQ ID NO.18) and mysA3-R (SEQ ID NO.19) to obtain the gene fragment mysA3.
[0115] ② Using the AB gene fragment as a template, PCR amplification was performed using primers mysB3-F (SEQ ID NO.20) and mysB3-R (SEQ ID NO.21) to obtain the gene fragment mysB3.
[0116] ③ The plasmid pRSFDuet1 was double-digested with NcoI and NotI and purified and recovered to obtain the pRSFDuet1 vector fragment.
[0117] ④Use the ClonExpressⅡ one-step cloning kit to connect the gene fragment mysA3, gene fragment mysB3 and pRSFDuet1 vector fragment, transform the connection product into E.coli XL1-Blue, pick the transformant for preliminary verification by colony PCR, then extract the plasmid for verification and sequencing to obtain the recombinant plasmid pRSFDuet1-mysA3B3.
[0118] ⑤ Using pRSFDuet1 as a template, use primers pRSF-T7-Not-F (SEQ ID NO.22) and pRSF-T7-Nde-R (SEQ ID NO.23) to perform PCR amplification to obtain the T7 promoter;
[0119] Using the CD gene fragment as a template, PCR amplification was performed using primers mysC3-F (SEQ ID NO. 24) and mysC3-R (SEQ ID NO. 25) to obtain the gene fragment mysC3;
[0120] Using the CD gene fragment as a template, PCR amplification was performed using primers mysD3-F (SEQ ID NO. 26) and mysD3-R (SEQ ID NO. 27) to obtain the gene fragment mysD3;
[0121] ⑥ The recombinant plasmid pRSFDuet1-mysA3B3 was double-digested with enzymes NdeI and XhoI and purified and recovered to obtain the pRSFDuet1-mysA3B3 vector fragment;
[0122] ⑦Use the ClonExpressⅡ one-step cloning kit to connect the T7 promoter, gene fragment mysC3, gene fragment mysD3, and pRSFDuet1-mysA3B3 vector fragment, transform the connection product into E.coli XL1-Blue, pick the transformants for preliminary verification by colony PCR, then extract the plasmid for verification and sequencing, and obtain the recombinant plasmid pRSFDuet1-T7×4-mysA3B3C3D3.
[0123] The recombinant plasmid pRSFDuet1-T7×4-mysA3B3C3D3 was transformed into E.coli BL21 using the same transformation method as above. 100 μL of the transformation solution was applied to LB solid medium containing 50 μg / mL Kan and cultured at 37°C for 12 hours until a single colony grew. A single colony was selected for PCR verification and sequencing screening to obtain a positive transformant, i.e., the recombinant strain E.coli BL21 / pRSFDuet1-T7×4-mysA3B3C3D3.
[0124] The recombinant strain E. coli BL21 / pRSFDuet1-T7×4-mysA3B3C3D3 was inoculated into LB liquid medium containing 50 μg / mL Kan at a ratio of 1% (v / v) and cultured until OD 600 Reached about 0.6; added IPTG with a final concentration of 0.2mM and induced culture at 25℃ for 25h.
[0125] After the induction culture, the culture solution was centrifuged at 10000 rpm for 5 min, the bacterial precipitate was collected, washed twice with PBS buffer and resuspended, and the resuspended solution was crushed using an ultrasonic crusher (ultrasonication for 4 s and pause for 4 s), power 400w, ultrasonication for 20 min. Whole cell samples and whole intracellular samples were prepared (preparation method is the same as above), and protein expression was analyzed by 12% SDS-PAGE.
[0126] The results are as follows Figure 2As shown, Figure A is a schematic diagram of the construction and gene cluster of E.coli BL21 / pRSFDuet1-T7×4-mysA3B3C3D3; Figure B is a schematic diagram of protein expression of E.coli BL21 and E.coli BL21 / pRSFDuet1-T7×4-mysA3B3C3D3, M: 180kDa Prestained Protein Marker, lanes 1-2: schematic diagram of whole cell and intracellular protein expression of E.coli BL21 blank control, lanes 3-4: schematic diagram of whole cell and intracellular protein expression of E.coli BL21-Ⅲ, lanes 5-6: schematic diagram of whole cell and intracellular protein expression of E.coli BL21 / pRSFDuet1-T7×4-mysA3B3C3D3.
[0127] Depend on Figure 2 It was found that after the introduction of the cascade promoter T7, the expression levels of MysA, MysB, MysC, and MysD proteins in E. coli BL21 / pRSFDuet1-T7×4-mysA3B3C3D3 were significantly increased. Although the expression level of MysC protein was still relatively low among all target proteins, its expression level was still slightly increased compared with the condition without the cascade promoter T7. The above results show that the introduction of the cascade promoter T7 can effectively promote the expression of target proteins, thereby improving the synthesis efficiency of Shinorine.
[0128] Example 3: Extraction and detection of shinorine in engineered strains E. coli BL21-III and E. coli BL21 / pRSFDuet1-T7×4-mysA3B3C3D3
[0129] 1. Extraction of Shinorine
[0130] The engineered strains E. coli BL21-Ⅲ and E. coli BL21 / pRSFDuet1-T7×4-mysA3B3C3D3 were activated at 37°C for 6 h using LB liquid culture medium; the activated bacterial solution was inoculated into LB liquid culture medium at a ratio of 2% (v / v) and the bacterial cell concentration was cultured to OD 600 was 0.6; IPTG with a final concentration of 0.2 mM was added and induced at 25°C for 20 hours to obtain a fermentation broth containing Shinorine; E. coli BL21 was used as a blank control.
[0131] After the induction culture, the fermentation liquid containing Shinorine was centrifuged at 10000rpm for 5min, the bacterial precipitate was collected, washed twice with PBS buffer and resuspended, and the resuspended liquid was crushed using an ultrasonic crusher (ultrasonication for 4s and pause for 4s), with a power of 400w and ultrasonication for 20min. The ultrasonicated liquid was centrifuged at 10000rpm for 20min, the supernatant was collected, an equal volume of methanol was added to the supernatant, and it was extracted at 37°C for 2h, and then ultrasonicated in an ultrasonic bath (100w) for 1h. The ultrasonicated mixed liquid was centrifuged at 10000rpm for 20min at 4°C to remove polysaccharides, proteins, nucleic acids and other substances, and the supernatant was subjected to low-temperature rotary evaporation at 30°C and freeze-dried at -70°C to obtain a freeze-dried sample containing Shinorine, i.e., a crude extract of Shinorine, which was stored at -80°C.
[0132] 2. Detection of Shinorine
[0133] The extracted freeze-dried sample was dissolved in ultrapure water, and the impurities were filtered out with a 0.22 μm filter membrane before HPLC detection, with E. coli BL21 as a blank control.
[0134] Test results such as Figures 3 to 6 As shown, Figure 3 This is the HPLC detection spectrum of E.coli BL21 blank control. Figure 4 This is the HPLC detection spectrum of E.coli BL21-Ⅲ. Figure 5 This is the HPLC detection spectrum of E.coli BL21 / pRSFDuet1-T7×4-mysA3B3C3D3. Figure 6 Comparison of Shinorine and Mycosporine-glycine production of E. coli BL21-Ⅲ and E. coli BL21 / pRSFDuet1-T7×4-mysA3B3C3D3.
[0135] Depend on Figures 3 to 5 Available, with Figure 3 compared to, Figures 4-5 Two significant absorption peaks were observed at approximately 7.4 min and 7.6 min, which were consistent with the expected retention times of Shinorine and Mycosporine-glycine, thus confirming that the engineered strains E. coli BL21-Ⅲ and E. coli BL21 / pRSFDuet1-T7×4-mysA3B3C3D3 were able to produce Shinorine.
[0136] Depend on Figure 6It was found that the peak area comparison method was used to estimate the production of Shinorine and Mycosporine-glycine in different strains. The peak area of Shinorine and Mycosporine-glycine in BL21-III was used as a reference standard to evaluate the production in BL21-III (T7) (E. coli BL21 / pRSFDuet1-T7×4-mysA3B3C3D3). The results showed that the production of Shinorine and Mycosporine-glycine in BL21-III (T7) was increased by 1.56 times and 1.22 times compared with BL21-Ⅲ, respectively. The above results show that the engineered strain E. coli BL21 / pRSFDuet1-T7×4-mysA3B3C3D3 after cascade T7 promoter transformation can effectively enhance the biosynthesis efficiency of Shinorine and Mycosporine-glycine and improve the production compared with E. coli BL21-Ⅲ.
[0137] Example 4: Cell proliferation-toxicity test of crude shinorine extract
[0138] Human skin keratinocytes (HaCaT) are a human skin cell line that can simulate the response of real skin cells under laboratory conditions; human skin fibroblasts (HSF) are the main components of the dermis of the skin. They can continuously secrete a variety of key structural proteins. These components together build the framework of the skin, which can effectively resist the challenges brought by aging, slow down the appearance of aging signs such as wrinkle formation and skin sagging. In addition, the many growth factors and cytokines released by HSF play a vital role in promoting the regeneration and repair of damaged skin. The following experiment uses the above two cells as experimental research objects to explore the application effect of crude extracts containing Shinorine in skin repair.
[0139] 1. Cell Culture
[0140] Take out the frozen cells HaCaT and HSF from liquid nitrogen, quickly put them into a 37°C water bath, and after the cell suspension is completely dissolved, transfer the HaCaT and HSF cells to 1.5 mL sterile centrifuge tubes, centrifuge at 1000 rpm for 5 min, discard the supernatant, and resuspend the cells with fresh DMEM complete medium (HaCaT uses high-glucose DMEM complete medium, and HSF uses low-glucose DMEM complete medium) to obtain a cell suspension.
[0141] The cell suspension was transferred into a T25 cell culture flask containing 5 mL of DMEM complete medium preheated at 37° C. The T25 cell culture flask was placed in a carbon dioxide incubator and cultured for 24 h to allow the cells to adhere.
[0142] When the cell confluence reaches 70-80%, the cells are passaged and the waste liquid is discarded. The cells are washed twice with PBS buffer preheated at 37°C, and then 0.25% trypsin is added to cover the cell surface. The cells are digested in a carbon dioxide incubator for 7 minutes and gently tapped until the cells are completely detached from the wall. Fresh DMEM complete medium containing FBS is added to terminate the digestion, and the cells are inoculated into the well plate for subsequent experiments.
[0143] 2. Cell proliferation-toxicity test
[0144] This experiment intends to evaluate whether the crude extract of Shinorine will be toxic to cells by observing the survival rate of HaCaT and HSF. The specific experimental method is as follows:
[0145] Take 40 mg of each freeze-dried sample containing Shinorine prepared by the engineered strains E. coli BL21-Ⅲ and E. coli BL21 / pRSFDuet1-T7×4-mysA3B3C3D3 in Example 3 (hereinafter referred to as "Shinorine crude extract"), dissolve them in 2 mL of ultrapure water, filter out impurities with a 0.22 μm filter membrane, and set aside; the intracellular extract of E. coli BL21 prepared by the same method was used as a negative control.
[0146] HaCaT in the logarithmic growth phase was taken at 1.5×10 4 Cells were seeded at a density of 100 μL per well in a 96-well plate and cultured at 37°C for 24 h. The cells were then washed twice with PBS buffer to remove non-adherent cells, and 100 μL of fresh high-glucose DMEM complete medium containing 0.1 mg / mL, 0.5 mg / mL, 1.0 mg / mL, 2.5 mg / mL, 5.0 mg / mL, 7.5 mg / mL, 10 mg / mL and 20 mg / mL Shinorine crude extract was added, respectively. High-glucose DMEM complete medium was used as a blank control (BC), and high-glucose DMEM complete medium containing 3% (v / v) DMSO was used as a positive control. The cells were incubated at 37°C, 5% CO2 for 24 h, and then 100 μL of working solution containing 10% (v / v) CCK-8 (CCK-8 kit purchased from Tongren Chemical Research Institute) was used. The cells were continued to be incubated at 37°C, 5% CO2 for 1 h, and the absorbance value was measured at 450 nm.
[0147] Take HSF in the logarithmic growth phase and use 1×10 4Cells were seeded at a density of 100 μL per well in a 96-well plate, and cultured at 37°C for 24 h. The cells were then washed twice with PBS buffer to remove non-adherent cells, and 100 μL of fresh low-glucose DMEM complete medium containing 0.1 mg / mL, 0.2 mg / mL, 0.5 mg / mL, 1.0 mg / mL, 2.5 mg / mL, 5.0 mg / mL, 10 mg / mL and 20 mg / mL of Shinorine crude extract was added, respectively. The low-glucose DMEM complete medium was used as a blank control (BC), and the high-glucose DMEM complete medium containing 3% (v / v) DMSO was used as a positive control. The plates were incubated at 37°C, 5% CO2 for 24 h, and then 100 μL of working solution containing 10% (v / v) CCK-8 was used. The plates were incubated for another 1 h at 37°C, 5% CO2, and the absorbance was measured at 450 nm.
[0148] The cell proliferation rate was calculated according to the following formula:
[0149] Cell proliferation rate (%) = (A1-A 空白 ) / (A0-A 空白 )×100%;
[0150] Among them, A1: absorbance value of the well with cells, CCK-8 and intracellular extract; A0: absorbance value of the well with cells, CCK-8 but no intracellular extract; A 空白 : Absorbance values of wells with DMEM complete medium and CCK-8 but without cells.
[0151] Toxicity test results:
[0152] (1) Toxicity test results of HaCaT
[0153] Test results such as Figure 7 As shown, Figure A represents the intracellular extract of E. coli BL21, Figure B represents the intracellular Shinorine crude extract of E. coli BL21-Ⅲ, and Figure C represents the intracellular Shinorine crude extract of E. coli BL21 / pRSFDuet1-T7×4-mysA3B3C3D3, among which, *p<0.05, **p<0.01, ***p<0.001, vs. blank control group (BC).
[0154] Depend on Figure 7It can be seen that when the concentration is lower than 5 mg / mL, the intracellular extract of E. coli BL21 has no cytotoxicity to HaCaT; when the concentration is lower than 7.5 mg / mL, the intracellular Shinorine crude extracts of E. coli BL21-Ⅲ and E. coli BL21 / pRSFDuet1-T7×4-mysA3B3C3D3 have no cytotoxicity to HaCaT.
[0155] (2) Toxicity test results of HSF
[0156] Test results such as Figure 8 As shown, Figure A represents the intracellular extract of E. coli BL21, Figure B represents the intracellular Shinorine crude extract of E. coli BL21-Ⅲ, and Figure C represents the intracellular Shinorine crude extract of E. coli BL21 / pRSFDuet1-T7×4-mysA3B3C3D3, among which, *p<0.05, **p<0.01, ***p<0.001, vs. blank control group (BC).
[0157] Depend on Figure 8 It can be found that when the concentration is lower than 0.2 mg / mL, the intracellular extract of E. coli BL21 has no cytotoxicity to HaCaT; when the concentration is lower than 1.0 mg / mL, the crude intracellular Shinorine extract of E. coli BL21-Ⅲ has no cytotoxicity to HaCaT; when the concentration is lower than 0.5 mg / mL, the crude intracellular Shinorine extract of E. coli BL21 / pRSFDuet1-T7×4-mysA3B3C3D3 has no cytotoxicity to HaCaT.
[0158] Example 5: Cellular scratch repair test of crude shinorine extract
[0159] This experiment intends to evaluate the ability of cell migration by observing and analyzing the process of cell migration to the scratch area, thereby determining the effect of Shinorine on cell repair. The specific experimental methods are as follows:
[0160] Press 5×10 5HaCaT was inoculated into a 6-well plate at a cell density of 2 mL per well, and cultured at 37°C for 24 h. Under the microscope, it was observed that the cells in each culture well were full, closely connected, and the degree of fusion reached 100%. Then, with the help of a ruler, a 10 μL pipette tip was quickly used to vertically point to the bottom of the cell culture plate, and a straight line was evenly drawn on the monolayer of cells. Washed twice with PBS buffer, the cells that fell off after the scratch were removed, and replaced with fresh high-glucose DMEM complete medium containing 1 mg / mL Shinorine crude extract. At the same time, high-glucose DMEM complete medium was used as a blank control (BC), high-glucose DMEM complete medium containing 1 μg / mL epidermal growth factor (EGF) was used as a positive control, and the intracellular extract of E. coli BL21 containing the same concentration was used as a negative control. Continue to culture at 37°C for 24 h, observe under a fluorescent inverted microscope and take pictures for record.
[0161] Press 3×10 5 HSF was inoculated into 6-well plates at a cell density of 100 / well, 2 mL per well, and cultured at 37°C for 24 hours. Under the microscope, it was observed that the cells in each culture well were full, closely connected, and the degree of fusion reached 100%. Then, with the help of a ruler, a 10 μL pipette tip was quickly used to vertically draw a straight line on the monolayer of cells perpendicular to the bottom of the cell culture plate. Wash twice with PBS buffer to remove the cells that fell off after the scratch, and replace with fresh low-glucose DMEM complete medium containing 0.1 mg / mL and 0.2 mg / mL Shinorine crude extract. At the same time, low-glucose DMEM complete medium was used as a blank control (BC), low-glucose DMEM complete medium containing 100 μg / mL vitamin C (VC) was used as a positive control, and E. coli BL21 intracellular extract containing the same concentration was used as a negative control. Continue to culture at 37°C for 24 hours, observe and take pictures under a fluorescent inverted microscope, and use Image J to process the pictures and record the scratch area.
[0162] Cell scratch repair test results:
[0163] (1) HaCaT cell scratch repair test results
[0164] Test results such as Fig. 9 As shown, Figure A is the scratch pictures of HaCaT at 0h and 24h, and Figures B and C are the changes in the migration area of HaCaT; a, b, and c are the intracellular extracts of E.coli BL21, the crude intracellular Shinorine extracts of E.coli BL21-Ⅲ, and the crude intracellular Shinorine extracts of E.coli BL21 / pRSFDuet1-T7×4-mysA3B3C3D3, respectively; *p<0.05, **p<0.01, ***p<0.001, vs. blank control group (BC).
[0165] Depend on Fig. 9 It was found that the crude Shinorine extract from E.coli BL21 / pRSFDuet1-T7×4-mysA3B3C3D3 cells could significantly promote the migration of HaCaT, with a migration area of 3.788. Although it was slightly lower than the repair effect of epidermal growth factor, it was 0.727 higher than the migration area of E.coliBL21 and 1.211 higher than the migration area of E.coli BL21-Ⅲ. The migration area of E.coli BL21-Ⅲ was lower than that of E.coli BL21, but still higher than that of the blank control group (BC). The above results show that the crude intracellular Shinorine extracts of the engineered strains E. coli BL21-Ⅲ and E. coli BL21 / pRSFDuet1-T7×4-mysA3B3C3D3 provided by the present invention both have the effect of repairing HaCaT, among which the crude intracellular Shinorine extract of E. coli BL21 / pRSFDuet1-T7×4-mysA3B3C3D3 has the best repair effect, which can significantly promote the migration of HaCaT and promote wound healing.
[0166] (2) Results of HSF cell scratch repair test
[0167] Test results such as Fig.10 As shown, Figure A is the scratch pictures of HSF at 0h and 24h, and Figures B and C are the changes in the migration area of HSF; a, b, and c are E.coli BL21 intracellular extract, E.coli BL21-Ⅲ intracellular Shinorine crude extract, and E.coli BL21 / pRSFDuet1-T7×4-mysA3B3C3D3 intracellular Shinorine crude extract, respectively; *p<0.05, **p<0.01, ***p<0.001, vs. blank control group (BC).
[0168] Depend on Fig.10It can be seen that the migration areas of HSF to intracellular extracts of E.coli BL21 with different concentrations are not much different, all lower than the migration area of crude Shinorine extracts in cells of engineering strains; the migration areas of crude Shinorine extracts in cells of E.coli BL21-Ⅲ with concentrations of 0.1 mg / mL and 0.2 mg / mL are 4.112 and 4.647, respectively, which are 1.679 and 2.214 higher than the migration areas of the BC group; except for the positive control group (VC), after treatment with 0.1 mg / mL crude Shinorine extracts in cells of E.coli BL21 / pRSFDuet1-T7×4-mysA3B3C3D3, HSF had the strongest migration and proliferation ability, with a migration area of 5.481, which is 3.048 higher than the migration area of the BC group. The above results show that based on HSF cells, Shinorine crude extract can significantly promote the migration of cell HSF and has anti-aging effects. Among them, the anti-aging effect of Shinorine crude extract in E.coli BL21 / pRSFDuet1-T7×4-mysA3B3C3D3 cells at a concentration of 0.1 mg / mL is the best.
[0169] Example 6: Anti-aging Study of Shinorine Crude Extract
[0170] MMP-1 (matrix metalloproteinase) is mainly responsible for decomposing collagen. It degrades collagen and elastin in the skin, causing the skin structure to loosen. It is one of the key factors causing skin aging and tumor invasion. Inhibiting the expression of MMP-1 can reduce the appearance of wrinkles and sagging, and maintain the firmness and elasticity of the skin.
[0171] This experiment intends to detect anti-aging related biochemical indicators to determine the anti-aging effect of Shinorine. The specific experimental methods are as follows:
[0172] Take HSF in the logarithmic growth phase and take 2×10 5 The cells were inoculated into 6-well plates at a density of 100 cells / well, 2 mL per well, and cultured at 37°C for 24 h, then replaced with PBS buffer for further culture. Except for the negative control group (NC), all other groups were irradiated with UV-A for 20 min at a dose of 9 J / cm 2 (Or use UV-B irradiation, irradiation time is 20min, dose is 1J / cm 2); After irradiation, the cells were washed twice with PBS buffer to remove the detached cells, and then divided into groups for drug administration. 2 mL of low-glucose DMEM complete medium was added to each well of the blank control group (BC) and the negative control group (NC), and low-glucose DMEM complete medium containing a final concentration of 100 μg / mL vitamin C (VC) was added to each well of the positive control group. Low-glucose DMEM complete medium containing a final concentration of 0.1 mg / mL and 0.2 mg / mL Shinorine crude extract (the same concentration of intracellular extract for E. coli BL21) was added to the sample groups, respectively, and cultured for 24 hours at 37°C and 5% CO2. After the culture, the cell culture medium was collected, and the expression changes of MMP-1 and COL-I (type I collagen) were detected using the MMP-1 activity detection kit and the COL-1 activity detection kit.
[0173] Test results:
[0174] (1) Expression of MMP-1
[0175] Test results such as Fig.11 As shown, Figure A shows the MMP-1 expression level of UV-A model, and Figure B shows the MMP-1 expression level of UV-B model; where a, b, and c are E. coli BL21 intracellular extract, E. coli BL21-Ⅲ intracellular Shinorine crude extract, and E. coli BL21 / pRSFDuet1-T7×4-mysA3B3C3D3 intracellular Shinorine crude extract, respectively; *p<0.05, **p<0.01, ***p<0.001, vs. negative control group (NC).
[0176] Depend on Fig.11 It was found that the expression of MMP-1 increased significantly under UV-A or UV-B modeling, and Shinorine crude extracts could significantly inhibit the expression of MMP-1. Among them, under UV-A modeling, 0.2 mg / mL of Shinorine crude extracts in E. coli BL21-Ⅲ cells could inhibit the expression of MMP-1 to 413.60 pg / mL, and 0.2 mg / mL of Shinorine crude extracts in E. coli BL21 / pRSFDuet1-T7×4-mysA3B3C3D3 cells could inhibit the expression of MMP-1 to 361.66 pg / mL, which was lower than the positive control group (396.05 pg / mL). The above results show that the inhibitory effect of Shinorine crude extracts on MMP-1 is better than drug treatment at an appropriate concentration.
[0177] (2) Expression of COL-1
[0178] Test results such as Fig.12 As shown, Figure A shows the expression level of COL-1 in UV-A model, and Figure B shows the expression level of COL-1 in UV-B model; where a, b, and c are E. coli BL21 intracellular extract, E. coli BL21-Ⅲ intracellular Shinorine crude extract, and E. coli BL21 / pRSFDuet1-T7×4-mysA3B3C3D3 intracellular Shinorine crude extract, respectively; *p<0.05, **p<0.01, ***p<0.001, vs. negative control group (NC).
[0179] Depend on Fig.12 It can be seen that under UV-A or UV-B modeling, the expression level of COL-1 showed a significant decrease. Among them, under UV-A modeling, the intracellular extracts of E.coli BL21, E.coli BL21-Ⅲ and E.coli BL21 / pRSFDuet1-T7×4-mysA3B3C3D3 can all upregulate the expression of COL-1, among which E.coli BL21-Ⅲ has the best effect. The intracellular Shinorine crude extract of E.coli BL21-Ⅲ at concentrations of 0.1 mg / mL and 0.2 mg / mL increased the expression level of COL-1 to 85.71 pg / mL and 86.40 pg / mL, respectively, second only to the VC group; the promoting effect of the intracellular Shinorine crude extract of E.coli BL21 / pRSFDuet1-T7×4-mysA3B3C3D3 at a concentration of 0.2 mg / mL on COL-1 was lower than that of the Shinorine crude extract of 0.1 mg / mL, which was 76.71 pg / mL. In the case of UV-B modeling, the intracellular extract of E. coli BL21 can significantly improve the expression of COL-1, but the crude extract of Shinorine in E. coli BL21 / pRSFDuet1-T7×4-mysA3B3C3D3 cells has no promoting effect on the production of COL-1. Based on the above results, it is speculated that Shinorine may exert its anti-aging effect through multiple mechanisms, not just relying on the regulation of COL-1.
[0180] In summary, the crude intracellular Shinorine extracts from the engineered strains E. coli BL21-Ⅲ and E. coli BL21 / pRSFDuet1-T7×4-mysA3B3C3D3 are substances with potential application value in skin care and anti-aging. In particular, the crude intracellular Shinorine extracts of E. coli BL21 / pRSFDuet1-T7×4-mysA3B3C3D3 can achieve skin repair effects without the need to purify Shinorine. Its positive effects in promoting cell repair and inhibiting key aging indicators provide a solid scientific basis for its future applications.
Claims
1. Application of a Shinorine production engineering strain in skin repair; in, The Shinorine production engineering strain is obtained by introducing AB gene fragments and CD gene fragments into Escherichia coli through a vector. The nucleotide sequence of the AB gene fragment is shown in SEQ ID NO.4, and the nucleotide sequence of the CD gene fragment is shown in SEQ ID NO.
5.
2. The use according to claim 1, characterized in that The vector is a pETDuet1 plasmid vector.
3. The use according to claim 2, characterized in that The introduction positions of the AB gene fragment and the CD gene fragment in the pETDuet1 plasmid vector are: the AB gene fragment is seamlessly cloned into the PstI restriction site of the pETDuet1 plasmid vector, and the CD gene fragment is introduced between the NdeI-XhoI restriction sites of the pETDuet1 plasmid vector.
4. The use according to claim 1, characterized in that The skin repair is cell repair and / or anti-aging.
5. The use according to claim 4, characterized in that The cell repair is skin keratinocyte (HaCaT) repair and / or human skin fibroblast (HSF) repair.
6. The use according to claim 1, characterized in that The Shinorine production engineering strain also contains a T7 promoter, and the nucleotide sequence of the T7 promoter is shown in SEQ ID NO.
28.
7. The use according to claim 1, characterized in that The application method is: inoculate the bacterial liquid of the Shinorine production engineering strain into LB liquid medium for cultivation. 600 When the pH value is 0.5 to 0.7, IPTG is added at a final concentration of 0.1 to 0.5 mM, and the culture is induced at a culture temperature of 25 to 30° C. for 20 to 36 hours to obtain a fermentation liquid containing Shinorine.
8. The use according to claim 7, characterized in that The bacteria in the fermentation broth are collected, washed with PBS buffer and resuspended, the resuspended liquid is subjected to the first ultrasonication and centrifugation, the supernatant is collected, methanol is added to the supernatant for extraction, and then the supernatant is subjected to the second ultrasonication and centrifugation, the supernatant is collected, and the supernatant is subjected to rotary evaporation at 30-35°C and freeze-drying at -70°C to obtain a lyophilized crude extract containing Shinorine.
9. The use according to claim 7, characterized in that The conditions of the first ultrasonic centrifugation are: power 400w, ultrasonic time 20min; the conditions of the second ultrasonic centrifugation are: power 100w, ultrasonic time 1h.
10. The use according to claim 7, characterized in that The final concentration of IPTG was 0.2 mM.
Citation Information
Cited By
Recombinant plasmid for preparing natural sun-screening agents shirinine and porphyra-334 and application of recombinant plasmid
CN121737182A
Recombinant plasmid for preparing natural sunscreen shinorine and porphyra-334 and application thereof
CN121737182B
Recombinant plasmid for preparing natural sun-screening agent shirinine and application of recombinant plasmid
CN121759501A
